Health Care [ 2/12 ] | Biotechnology [ 3/73 ]
NASDAQ | Common Stock
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors.
Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma.
It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate.
Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 14, 25 | -0.30 Decreased by -3.45% | -0.34 Increased by +11.76% |
| Jun 11, 25 | -0.35 Decreased by -483.33% | -0.24 Decreased by -45.83% |
| Mar 19, 25 | -1.32 Decreased by -300.00% | -0.32 Decreased by -312.50% |
| Nov 12, 24 | -0.35 Increased by +37.50% | -0.32 Decreased by -9.37% |
| Aug 11, 24 | -0.29 Increased by +29.27% | -0.32 Increased by +9.38% |
| May 14, 24 | -0.06 Increased by +89.09% | -0.24 Increased by +75.00% |
| Mar 21, 24 | -0.33 Increased by +67.33% | -0.47 Increased by +29.79% |
| Nov 7, 23 | -0.56 Increased by +34.12% | -0.51 Decreased by -9.80% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 2.82 M Increased by +N/A% | -18.35 M Decreased by -6.09% | Decreased by -650.85% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by -100.00% | -21.16 M Decreased by -549.82% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 3.40 M Decreased by -0.53% | -35.57 M Decreased by -128.06% | Decreased by -1.05 K% Decreased by -129.27% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -21.20 M Increased by +8.01% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -17.30 M Decreased by -8.80% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 16.15 M Increased by +N/A% | -3.26 M Increased by +81.43% | Decreased by -20.17% Decreased by N/A% |
| Dec 31, 23 | 3.42 M Increased by +N/A% | -15.60 M Decreased by -168.15% | Decreased by -456.05% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -23.05 M Increased by +14.49% | Decreased by N/A% Decreased by N/A% |